Pancreatitis News and Research RSS Feed - Pancreatitis News and Research

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS). [More]
Gene-encoded protein may be effective in early detection of pancreatic cancer

Gene-encoded protein may be effective in early detection of pancreatic cancer

A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center. [More]
Credentialed health care professionals have greater knowledge of evidence-based nutrition support practice

Credentialed health care professionals have greater knowledge of evidence-based nutrition support practice

Multidisciplinary health care professionals who hold the Certified Nutrition Support Credential (CNSC) scored significantly higher on a survey about their approaches to nutrition support practice than those who do not hold the credential according to new study. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver -- the event that makes the most common form of the disease lethal. By understanding this process, investigators say their discovery can lead to targeted treatments that delay metastasis, and could offer clinicians a new biomarker to test for the earliest signs of pancreatic cancer. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus. [More]
Houston woman gets $4,300 SNAP grant for necessary home repairs

Houston woman gets $4,300 SNAP grant for necessary home repairs

Wanda Richardson has been living on disability income since first being diagnosed with chronic pancreatitis 15 years ago. The high cost of covering her health care has made it difficult for her to finance needed home repairs. [More]
St. Mary's wins Distinguished Hospital Award for Clinical Excellence for second consecutive year

St. Mary's wins Distinguished Hospital Award for Clinical Excellence for second consecutive year

Dignity Health St. Mary's Medical Center has received the Distinguished Hospital Award for Clinical Excellence™ from Healthgrades, the leading online resource for comprehensive information about physicians and hospitals. This is the second consecutive year St. Mary's has received this award, which recognizes St. Mary's as among the top five percent of more than 4,500 hospitals nationwide for clinical performance. [More]
Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

National Institutes of Health researchers have uncovered a key factor in understanding the elevated cancer risk associated with gene therapy. They conducted research on mice with a rare disease similar to one in humans, hoping their findings may eventually help improve gene therapy for humans. Researchers at the National Human Genome Research Institute, part of NIH, published their research in the Jan. 20, 2015, online issue of the Journal of Clinical Investigation. [More]
VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity. [More]
FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO". [More]
FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. [More]
Advertisement
Advertisement